GAY, Francesca Maria

GAY, Francesca Maria  

BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE  

Mostra records
Risultati 1 - 14 di 14 (tempo di esecuzione: 0.007 secondi).
Titolo Data di pubblicazione Autore(i) File
A Case-Matched Analysis Comparing Lenalidomide After Autologous or After Allogeneic Stem Cell Transplantation Demonstrates a Survival Advantage in Allografted Myeloma Patients 2012 Vittorio Montefusco; Francesco Spina; Elena Zamagni; Benedetto Bruno; Francesca Gay; Francesca Patriarca; Giorgia Saporiti; Monica Galli; Claudia Crippa; Lucia Farina; Anna Maria Cafro; Angelo Michele Carella; Paolo Corradini
A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients 2010 Palumbo A; Falco P; Benevolo G; Rossi D; Carella AM; Guglielmelli T; Rocci A; De Paoli L; Grasso M; Mosca Siez ML; Piro E; Caltagirone S; Gay F; Cavallo F; Gaidano G; Boccadoro M
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (Mel200) Versus Melphalan 100 mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients. 2007 Palumbo A; Bringhen S; Petrucci MT; Falcone A; Liberati AM; Lauta VM; Grasso M; Montanaro M; Pisani F; Caravita T; Cangialosi C; Pregno P; Nozza A; Calabrese E; Gay F; Cavallo F; Omedè P; Musto P; Foà R; Boccadoro M
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS 2010 F Gay; A Larocca; MT Petrucci; P Musto; AM Liberati; V Callea; R Ria; T Caravita; C Cangialosi; M Grasso; M Offidani; P Pregno; F Patriarca; M Galli; M Cavo; L Catalano; C Nozzoli; T Guglielmelli; R Zambello; F Pisani; V Montefusco; F Rossini; V De Stefano; B Lupo; F Di Raimondo; G Gaidano; M Boccadoro; A Palumbo
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 2010 Rocci A; Gambella M; Trusolino L; Gay F; Omedè P; Magarotto V; Bertotti A; Montefusco V; Crippa C; Patriarca F; Gilestro M; Liberati AM; Gaidano G; Di Raimondo F; Falcone A; Rossi G; Drandi D; Corradini P; Ladetto M; Comoglio PM; Boccadoro M; Palumbo A
INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA 2006 P. Musto; I. Avonto; P.R. Scalzulli; B. Bruno; A. Falcone; M.T. Ambrosini; S. Bringhen; F. Gay; C. Rus; F. Cavallo; P. Falco; M. Massaia; M. Boccadoro; A. Palumbo
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 2009 Albero Rocci; Francesca Gay; Livio Trusolino; Paola Omedè; Andrea Bertotti; Vittorio Montefusco; Claudia Crippa; Francesca Patriarca; Milena Gilestro; Anna M. Liberati; Fausto Rossini; Tommaso Caravita; Antonietta Falcone; Giuseppe Rossi; Daniela Drandi; Paolo Corradini; Marco Ladetto; Paolo M. Comoglio; Mario Boccadoro; Antonio Palumbo
Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma. 2005 Palumbo A; Bringhen S; Musto P; Caravita T; Capozzi R; Callea V; Cangialosi C; Montanaro M; Catalano L; Grasso M; Petti MC; Merla M; Falchi L; Omedè P; Ceccarelli M; Ambrosini MT; Avonto I; Gay F; Falco P; Boccadoro M
Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma. 2005 Palumbo A; Falco P; Musto P; Corradini P; Di Raimondo R; Rossi G; Giuliani N; Morabito F; Luraschi A; Falcone A; Omedè P; Gay F; Avonto I; Ambrosini MT; Bringhen S; Zeldis J; Knight R; Boccadoro M; Petrucci MT
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 2013 Larocca, A; Bringhen, S; Evangelista, A; Offidani, M; Ballanti, S; Zaccaria, A; Pescosta, N; Montefusco, V; De Rosa, L; Carella, Am; Baldini, L; Aglietta, M; Vincelli, Id; Marasca, R; Pezzati, S; Tosi, P; Cocito, F; Grasso, M; Fioritoni, G; Pavone, V; Musto, P; Grammatico, S; Omede, P; Gay, F; Ciccone, G; Boccadoro, M; Palumbo, A
The AKT/mTOR/P70S6K/4EB-P1 Signaling Pathway Is Activated in a Subset of Multiple Myeloma Patients and Correlates with High Serum Levels of Beta 2-Microglobulin. 2008 T. Guglielmelli;S. Cappia;E. Giugliano;R. Merlini;E. Bacillo;F. Gay;P. Berchialla;D. Gregori;M. Papotti;A. Palumbo;G. Saglio
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy. 2009 Gay F; Bringhen S; Genuardi M; Rossi D; Ria R; Romano A; Ferrara F; Di Renzo N; Dominietto A; Andriani A; Rizzi R; Vallone R; Mele G; Storti S; Podda L; Aitoro G; Mettivier V; Annibali O; Rossini F; Gentilini P; Pavone V; Giuliani N; Rauco AM; Baraldi A; Capaldi A; Gherlinzoni F; Gaidano G; Boccadoro M; Palumbo A
Time to First Progression, but Not B2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy. 2006 Antonio Palumbo; Sara Bringhen; Patrizia Falco; Cecilia Rus; Federica Cavallo; Maria Teresa Ambrosini; Ilaria Avonto; Francesca Gay; Gabriele Gallone; Tommaso Caravita; Benedetto Bruno; and Mario Boccadoro
VelcadeTM Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma. 2005 Palumbo A; Ambrosini MT; Pregno P; Pescosta N; Callea V; Cangialosi C; Caravita T; Morabito F; Omedè P; Gay F; Avonto I; Falco P; Bringhen S; Boccadoro M